Checked
LianBio
OTC: LIANY · Pharmaceutical Preparations · Princeton, NJ
- Net income
- -$110.3M
- Total assets
- $320M
- Diluted EPS
- -$1.02
Company details
As reported to the SEC
- SEC CIK
- 1831283
- Stock
- OTC: LIANY
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 103 Carnegie Center Drive, Suite 309, Princeton, NJ 08540
- Fiscal year end (SEC record)
- December 31
- Filer status
- , Emerging growth company
- Phone
- (609) 486-2308
- Last annual report
- 03/28/2023
- Last quarterly report
- 11/13/2023
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2022 | 12/31/2021 | 12/31/2020 |
|---|---|---|---|
| Operating income | -$125.4M | -$195.6M | -$134.9M |
| Net income | -$110.3M | -$196.3M | -$139.6M |
| Diluted earnings per share | -$1.02 | -$5.71 | -$11.58 |
| Research and development | $59.76M | $158.7M | $120.9M |
| Total assets | $320M | $426.3M | $279.3M |
| Total liabilities | $26.31M | $39.01M | $27.57M |
| Shareholders' equity | $259.9M | $353.6M | -$132.8M |
| Cash and cash equivalents | $79.22M | $228.2M | $254.3M |
| Cash from operations | -$99.19M | -$164M | -$98.14M |
| Capital expenditures | $1.84M | $947K | $886K |
Subsidiaries
12 companies that LianBio owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Lian Cardiovascular | SEC 10-K |
| Lian Oncology Limited | SEC 10-K |
| LianBio Development (Cayman) Limited | SEC 10-K |
| LianBio Development (HK) Limited | SEC 10-K |
| LianBio Development (SG) Pte. LTD. | SEC 10-K |
| LianBio Inflammatory Limited | SEC 10-K |
| LianBio Licensing, LLC | SEC 10-K |
| LianBio Ophthalmology Limited | SEC 10-K |
| LianBio Respiratory Limited | SEC 10-K |
| Shanghai LianBio Cardiovascular Development Co., Ltd. | SEC 10-K |
| Shanghai LianBio Development Co., Ltd. | SEC 10-K |
| Shanghai LianBio Oncology Development Co., Ltd. | SEC 10-K |
Recent filings
72 recent filings on record
Swipe the table sideways to see more columns.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 27, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is LianBio's CIK number?
- LianBio's SEC Central Index Key (CIK) is 1831283.
- What is LianBio's stock ticker?
- LianBio trades as OTC: LIANY.
- When does LianBio's fiscal year end?
- LianBio's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2022.
- Where is LianBio headquartered?
- LianBio's principal executive office on file with the SEC is in Princeton, NJ.
- What companies does LianBio own?
- LianBio lists 12 subsidiaries in its SEC filings and other public records, including Lian Cardiovascular, Lian Oncology Limited, LianBio Development (Cayman) Limited.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/27/2026